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Abstract
Background: Current research indicates that obese individuals have cognitive deficits in executive function, leading
to difficulties with planning, impulse control and decision-making. High levels of inflammation have been proposed
to contribute to executive function deficits in individuals with obesity.
Methods/design: One hundred and seventy-six obese participants will be randomly assigned to one of two
groups: (1) behavioural weight loss alone (BWL) group = 8 sessions of individual BWL sessions plus 12 group BWL
sessions or (2) Cognitive Remediation Therapy for Obesity (CRT-O) plus BWL group (CRT-O + BWL) = 8 sessions of
individual CRT-O plus 12 group BWL sessions. The study is double blind – participants will only be told that two
weight-loss treatments are being compared and research assistants conducting outcome assessments will not
know participants’ group allocation. Blood tests will be conducted to measure inflammatory markers. Measurement
points will be at baseline, post treatment and 1-year follow-up. The primary outcomes will be differences between
treatment groups in percentage weight loss, executive function, binge eating and an examination of whether
changes in executive function predict changes in weight and binge eating. Secondary outcome measures will
examine changes on inflammation, quality of life, and grazing behaviour and whether these predict changes in
executive function and weight.
Discussion: If CRT-O + BWL is more effective in assisting people to lose weight long term than BWL alone it should
significantly improve treatment outcomes. This study expands upon our recent trial which showed that CRT-O
enhanced executive function and weight loss in obese adults. The current study is strengthened by several factors:
it is double-blind, it uses an active control, has a larger sample size, and measures inflammation to examine the
mechanisms.
Trial registration: The RCT is registered with the Australian New Zealand Registry of Clinical Trial, trial identifier:
ACTRN12616000658415. Registered on 20 May 2016.
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Background
According to the World Health Organisation more
than 1.9 billion adults are overweight and of these
600 million are obese [1]. Between 1980 and 2014,
the prevalence of obesity has more than doubled [1].
In Australia, the economic costs of obesity have been
estimated at AU$21 billion a year [2]. Furthermore,
the disability associated with obesity and its conse-
quences has been calculated at over 36 million
disability-adjusted life years, due mainly to ischemic
heart disease and type 2 diabetes [3]. The comorbidi-
ties related to obesity, such as type 2 diabetes and
coronary heart disease, however, are alleviated by
modest weight loss [4] and long-term maintenance of
the reduced weight [5]. Recommendations for obese
individuals include losing 5–10% of body weight, and
maintaining the loss, in order to reduce the risk of
developing chronic medical conditions [6]. Whilst a
number of current interventions assist individuals to
reduce 5–10% of their body weight, most people re-
gain the weight once professional contact ends [7].
Therefore, new treatment interventions which assist
with weight-loss maintenance are urgently needed.
Recent research has examined the role of executive
function in individuals with obesity. Executive func-
tion refers to a range of higher-order cognitive pro-
cesses that facilitate initiation, planning, inhibition,
cognitive flexibility, working memory, self-regulation,
sequencing, and the achievement of complex, goal-
oriented behaviour [8]. Obesity has been linked to
deficits in executive function. A review of 24 studies
found highly consistent results, with 22 studies show-
ing a negative association between obesity and execu-
tive function [9]. This finding remained consistent
even after controlling for age, sex, education, socio-
economic status, smoking, and cardiovascular and
metabolic markers. Obese individuals with and with-
out binge-eating disorder (BED) have been shown to
have similar cognitive deficits [10]. In combination,
these findings support a link between obesity and def-
icits in executive functioning, irrespective of common
psychological or medical comorbidities.
The exact mechanism through which obesity and
cognitive function are linked remains unknown. Smith
and colleagues [9] have argued that a bidirectional re-
lationship between executive function and obesity
may be present whereby obesity impairs executive
function via biological mechanisms, such as glucose
abnormalities or inflammatory markers, and deficits
in executive function exacerbate weight gain by caus-
ing difficulties with the regulation of food intake, and
an inability to plan ahead or inhibit responses or a
tendency to act impulsively. Research supports the
notion that executive functioning is an important
predictor of healthy eating, breakfast consumption
and the inhibition of alcohol consumption [11–13]
which are all predictors of obesity. Targeting these
deficits in the obese may potentially improve a per-
son’s response to therapy. This line of enquiry has led
to the development of a new form of treatment for
weight disorders, namely Cognitive Remediation Ther-
apy for Obesity (CRT-O) [9, 14].
CRT-O is a manualised, face-to-face treatment that
aims to improve underlying executive function deficits.
It consists of mental exercises aimed at improving cogni-
tive strategies, thinking skills and information processing
through practice [14]. CRT for Anorexia Nervosa (CRT-
AN) has been shown to be effective at improving execu-
tive function and eating-disorder-related quality of life
(post treatment) and reducing psychopathology (at 6-
month follow-up) [15]. Unlike CRT-AN, CRT-O is
intended to assist people to maintain weight loss and
prevent weight gain by associating cognitive style to food
intake and exercise behaviours.
Our recent randomised controlled trial (RCT) on
CRT-O for obesity [16] provided evidence for the effi-
cacy of CRT-O. Eighty obese individuals received three
90-min sessions of behavioural weight loss (BWL: a
standard weight-loss treatment) and were then rando-
mised to either eight sessions of individual face-to-face
CRT-O or a no-treatment control condition. Results
showed that those in the CRT-O group experienced a
significant improvement in executive function and a sig-
nificant decrease in weight compared to controls, both
with large effect sizes, and that changes in executive
function predicted changes in weight. Participants also
had a significant reduction in binge eating in the CRT-O
condition, compared to controls. This highlights that
CRT-O can improve executive function and help indi-
viduals to manage their weight. The data from this trial
suggests that CRT-O could enhance weight-loss out-
comes, without targeting eating or exercise behaviour
directly.
Our present RCT will endeavour to determine the ef-
fectiveness of eight individual sessions of CRT-O plus 12
group sessions of BWL compared to eight individual and
12 group sessions of BWL alone (standard care) in obese
patients, in terms of reducing weight, binge eating, graz-
ing, and improving executive function and quality of life.
In addition, as high levels of inflammation have been
proposed to contribute to executive function deficits in
obese individuals, inflammatory markers will be assessed
to test this hypothesis [17]. We hypothesise that those
who receive CRT-O plus BWL will show greater weight
loss, improved executive functioning and quality of life,
and reduced binge eating/grazing compared to individ-
uals in the BWL alone condition at post-treatment and
1-year follow-ups.
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Methods/design
Participants
Participants will be 176 individuals, aged 18–55 years,
with a Body Mass Index (BMI) ≥30.0 kg/m2 who can
provide informed consent, have sufficient English skills,
and are able to attend treatment on campus. Participants
are excluded if they have been diagnosed with somatic
conditions (e.g. neurological disorders, stroke, head in-
jury); serious psychiatric/psychosomatic conditions (e.g.
psychotic disorder, suicidality, severe substance use dis-
order, developmental or intellectual disability); impedi-
ment in hearing, vision, or language with an effect on
testing; previous or planned bariatric surgery; use of
medication that impacts weight or executive functioning
(e.g. antipsychotics, sedatives). These inclusion and ex-
clusion criteria will allow for recruitment of a represen-
tative study sample, heterogeneous with regard to body
weight, degree of obesity, and prevalence of typical
comorbidities.
Procedure
Participants will be recruited from clinic settings and
the community, with close to equal numbers of male
and female subjects (although more female subjects
are anticipated based on previous trials). Advertising
will also be placed on social media sites, community
notice boards and newspapers. Participants will be
asked to provide their contact details if they are inter-
ested in taking part in the study. The research psych-
ologist will telephone or email the participant to
make contact and to inform them about what is in-
volved. If the participant is interested in taking part,
the psychologist will conduct a screening interview to
assess whether the potential participant is suitable
and will schedule an assessment time.
This is a double-blind study; participants are blind
to the design of the study, i.e. they are not provided
with any information regarding the CRT-O interven-
tion prior to randomisation and research assistants
are blind to the participants’ group allocation at post-
treatment and follow-up assessments. Participants are
informed that two different weight-loss treatments are
being compared. Participants will be required to have
a GP who is responsible for their medical manage-
ment during the trial. Participants will be randomly
assigned to one of two groups using computer-
generated random numbers, provided in a document
developed by a researcher not in charge of recruit-
ment or assessment:
1. BWL alone group = 8 sessions of individual BWL
plus 12 sessions of group BWL or
2. CRT-O + BWL group = 8 sessions of individual
CRT-O plus 12 sessions of group BWL
The RCT has been registered with the Australian
New Zealand Registry of Clinical Trial (trial id:
ACTRN12616000658415). The trial followed the SPIRIT
guidelines (see additional file 1).
Behavioural weight-loss intervention (BWL)
Those in the BWL group will attend eight individual ses-
sions with a psychologist, where they will receive exten-
sive education about weight-loss techniques and receive
support towards achieving their weight-loss goals includ-
ing managing emotions, cravings and establishing hun-
ger cues. Following this, they will attend 12 weekly (2-h)
BWL group sessions which will teach them how to
change their diet and exercise habits to enable weight
loss. Treatment requires participants to record their diet
and exercise behaviour in a diary.
During these sessions the psychologist will reinforce
the BWL strategies and help the participant to problem-
solve any difficulties that they are having with their
implementation. The group programme is a modified
version of the Look Ahead trial [18, 19]. The Look
Ahead trial is an intensive lifestyle intervention
programme that targets diet and exercise through behav-
ioural modification techniques and has been extensively
researched [18, 19]. The programme has been modified
to include Australian dietary and physical activity guide-
lines. Interestingly, BWL programmes have been found
to be more successful at enhancing weight loss than cog-
nitive behavioural therapy [20].
During BWL, behavioural techniques are used to help
participants modify eating and exercise habits. A
dietitian will conduct an early BWL group session re-
garding dietary advice. Participants are taught to ma-
nipulate their environment at home and at work by
limiting cues associated with eating and increasing cues
associated with exercise. For example, participants are
encouraged to keep high-fat, high-calorie foods out of
their house and work area. Problem-solving techniques
are taught so that participants can effectively deal with
difficult situations that threaten their weight-control ef-
forts. Thoughts and emotions related to overeating and
inactivity are also addressed during treatment sessions
to understand and decrease the influence of these factors
on weight control. Stress management, craving exposure
and mindful eating techniques will be taught and atten-
tion is given to motivation enhancement and relapse
prevention to help individuals to maintain their weight
loss. Homework will also be provided.
Cognitive Remediation Therapy for Obesity (CRT-O)
CRT-O is a manualised intervention that consists of
mental exercises aimed at improving executive function
via practice [14]. CRT promotes reflection on thinking
styles, develops metacognition and helps to explore and
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apply new thinking strategies in everyday life. The pri-
mary function of CRT is to improve the thinking process
rather than the content [21–23]. A manual was devel-
oped for the pilot CRT-O trial. The current trial will also
utilise this manual. The CRT-O treatment will be deliv-
ered face-to-face by two clinical psychologists. The main
components and principles of CRT-O are based on the
original CRT-AN treatment. However, some important
modifications have been made to adapt the manual for
obesity and these are described in Smith et al. [14].
Homework will also be provided.
Assessment
Participants will complete a comprehensive assessment
at baseline, at post-treatment and 1-year follow-ups con-
sisting of:
1. Demographics: age, sex, ethnicity/race,
socioeconomic status (by postcode, income,
education), and language use
2. Anthropometric measures: we will measure: (1)
height and weight with calibrated scales (to derive
BMI in kg/m2), (2) hip and waist circumferences to
calculate the waist to hip ratio, and (3) we will use a
portable bioelectrical impedance scale (from Tanita)
to calculate an estimate of total body water, which
can then be used to estimate fat-free body mass and,
by difference with body weight, body fat. (One study
showed that Tanita and DEXA measures correlated
at 0.96 [24]). Weight will be measured at every
session
3. Exercise: participants will wear an accelerometer for
1 week (at three time points) to assess physical
activity levels. Accelerometers are effective tools that
continuously record physical activity over specified
time intervals. The data output also allows for an
estimate of physical activity intensity and energy
expenditure (which are not possible with alternative
methods, such as pedometers). To not over-burden
participants during assessment (week 0), the acceler-
ometer will be provided in week 1 of the
intervention
4. Neuropsychological assessment: a targeted
assessment of cognitive function will be completed
at the time of their preference. It will include:
Executive function: the Wisconsin Card Sorting Test
(WCST)-64: the computerised version of the WCST
[25, 26] will be used. In this test, subjects are
instructed to categorise a series of cards according
to one of three stimulus features (colour, shape or
number), without this principle being revealed to the
subject. After each association, the only feedback
given is whether a match is correct or incorrect, the
idea being that subjects should infer how to
categorise based on the feedback they receive. This
test measures categorisation, inference, testing of
hypotheses, cognitive flexibility, cognitive inhibition
and response to feedback [27]. The number of total
errors and perseverative errors and failure to
maintain a set are the dependent measures. The
WCST is regarded as a valid measure of abstract
reasoning ability to maintain and appropriate
planning and problem-solving strategies across chan-
ging stimulus conditions to obtain a future goal; it is
the most widely used test of executive function [28]
Trail Making Test (TMT) [29]: this will be used to
assess psychomotor speed, visual integration,
cognitive flexibility and inhibitory control. This test
measures the subject’s ability to connect written
numbers in an ascending order (Trail A), and,
afterwards, to connect numbers and letters,
alternating numbers in ascending order and letters
in alphabetical order (Trail B), for example, 1-A-2-B.
The score is the response time taken to complete
the respective trails [28]
Behaviour Rating Inventory of Executive Function
(BRIEF-A): participants will complete the BRIEF-A
Self-report Form. This instrument is a 75-item stan-
dardised measure that records views of an adult’s ex-
ecutive functions or self-regulation in a person’s
everyday environment. It has been shown to be a re-
liable and valid measure of executive functioning in
individuals across a broad age range [30]
Memory: Wechsler Memory Scale (WMS), Logical
Memory Subtest: the Logical Memory Test is the
most widely used measure of memory [31], and it
targets auditory-linguistic memory. The task de-
mands verbal recall of spoken story passages
Language: Boston Naming Test (BNT): the BNT is a
60-item confrontation naming test which is consid-
ered to be a reliable measure of word retrieval per-
formance [32]
5. Nutrition: a comprehensive assessment, using a 1-
week food diary, will be conducted by a dietitian and
will be analysed using FoodWorks software. The
Foodworks Professional package includes food com-
position tables and contains nutrient values for more
than 4200 foods, beverages and supplements. Food-
Works is suitable for dietary analysis and meal
planning
6. Inflammatory markers: tumor necrosis factor-α
(TNFα), interleukin-6 (IL-6), inflammasome-
activated IL-1β and C-reactive protein will be
measured
7. Clinical assessment: a brief clinical assessment will
verify comorbidities such as an eating disorder,
depression or anxiety. The participant will also be
asked questions related to their previous weight-loss
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attempts and beliefs about weight loss. The following
measures will also be completed:
(a)Depression, anxiety and stress: will be measured
by the 21-item Depression, Anxiety and Stress
Scale (DASS) [33], a well-validated Australian
measure. It has been validated in clinical and non-
clinical populations and has good reliability [33,
36]. Research has indicated that individuals who
are obese are at an increased risk of developing
depression and depression has been found to be
predictive of obesity [34]. Also, the association
between depression and obesity has been found
to have a dose-response gradient where the asso-
ciation between depression and obesity has been
found to be stronger than that between depres-
sion and being overweight [35]. There is a signifi-
cant evidence base that indicates that depressive
disorders are associated with deficits in cognition,
including difficulties with verbal learning and
memory [37], attentional functions, executive
control, lowered cognitive flexibility [38] and in-
terpretation biases [39, 40]
(b)Eating disorder symptoms: eating disorder
symptoms are to be measured by the Eating
Disorder Examination Questionnaire (EDE-Q)
[41]. The EDE-Q has 36 items and measures con-
cerns about shape, weight and eating; restraint
and self-reported binge eating. Subscale scores for
shape, weight and eating concerns and restraint
range between 0 and 6. A higher score indicates
more severe eating psychopathology. This has
been validated in community samples in Australia
and it has been shown to hold acceptable internal
consistency and test-retest reliability [42]. The
BED and purging subsections of the EDE will also
be administered
(c)Grazing Questionnaire: grazing refers to
‘uncontrolled, repetitive eating of small amounts
of food’. Grazing has been implicated as an eating
behaviour which is associated with obesity. This
measure is a 9-item self-report questionnaire
which asks specific questions regarding eating be-
haviour [43]
(d)Quality of Life: this will be assessed using the
Short Form-12 Health Status Questionnaire (SF-
12). This is a well-known and validated measure
of functional limitations associated with impair-
ment in physical and mental health
Treatment fidelity
The clinical psychologists delivering the treatment will
be trained and regularly supervised. Therapist adherence
will be monitored through audio-recordings and
monthly supervision sessions. Adverse events assessed
by the psychologists will be reported to the Ethics Com-
mittee immediately. A psychologist can refer a partici-
pant to another psychologist for treatment of mental
illness at any time. In addition, randomly selected taped
sessions of CRT and BWL will be reviewed by two of the
project’s principal researchers who will apply a previ-
ously developed Treatment Adherence Measure to the
taped sessions. The Work Alliance Inventory (WAI) will
be administered during weeks 4 and 8 of individual
treatment to assess therapeutic alliance. In weeks 4, 8
and 12 of group treatment, the Group Climate Scale
(GCS) will be provided to assess group factors. Session
attendance will also be recorded.
Data collection and analysis
Data is collected at baseline, post treatment and at 1-
year post-treatment follow-up. See Table 1 for assess-
ment tests and times of data collection. The Statistical
Package for Social Sciences (SPSS) statistics will be used
to analyse data. Data entry will be done and checked by
two research assistants and stored in the university’s ser-
ver. The principal researchers will conduct the analyses
Table 1 Assessment tests and times of data collection for both groups











Demographic data X X X
Anthropometric
measures
X X (at the end of one-to-one
intervention)
X X




Nutrition data X X X
Inflammatory markers X X X
Accelerometers X X X
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for the main results with assistance of trained statisti-
cians. The Data Monitoring Committee is comprised of
two researchers, one with expertise in cognitive remedi-
ation therapy and the other is the primary researcher
(ES).
Power calculations
We calculated the sample size with a method that
takes into account the intracluster correlation coeffi-
cient (r = .02) for comparison between groups using a
two-tailed linear mixed model, predicting a small ef-
fect size (Cohen’s d of 0.2) on weight loss and using
a power of 80%, and determined that a sample size of
70 individuals per group is needed. Assuming an at-
trition rate of 25% per group, a sample of 88 per
group is necessary, totalling 176 participants.
Main analyses
Analyses for the main results will be conducted by the
researchers with assistance from a statistician. Data will
be inspected for normality and nonparametric statistics
applied where appropriate. Percentage weight loss will
be computed. Scores on cognitive measures will be
transformed into z-scores. Linear mixed models will be
used to compare differences between treatment groups
in percentage weight loss, executive function, binge eat-
ing and to examine whether change in executive func-
tion predicted changes in weight and binge eating.
Secondary analyses
To examine the baseline and prospective relationships
between biological data and cognition/weight, linear or
logistic regression analyses will be performed whilst con-
trolling for potential confounders. The Bonferroni cor-
rection or FDR (False Discovery Rate) method will be
used for multiple comparisons and post-hoc testing will
be performed where appropriate. Secondary analyses for
the other secondary measures will use either linear
mixed models or repeated measure analysis of variance
(ANOVA). We will report the main analyses in a separ-
ate publication to secondary analyses.
Discussion
If CRT-O (plus BWL) is successful at assisting people to
lose weight and to maintain the weight loss it would
allow for the development of an intervention that could
significantly improve treatment outcomes. Given the
poor long-term outcomes for previously investigated
treatments (excepting bariatric surgery reserved for the
most severe cases) and the increasing public health bur-
den of obesity, novel and integrative treatment ap-
proaches are urgently needed.
Our RCT is designed to compare two groups, a CRT-
O (plus BWL) group to a BWL alone group. We will
investigate whether CRT-O (plus BWL) is effective in
improving a person’s ability to lose weight, to maintain
their weight loss and to improve their executive func-
tioning, compared to BWL alone. The strengths of our
design include its large sample size, the use of validated
and standardised assessments, and its double-blind study
design. We will also be the first to measure inflamma-
tory markers to discern whether there is an association
between inflammation, weight and executive function in
obese individuals.
Trial status
Trial has started recruiting participants in September
2016.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 122 kb)
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